Next Science Ltd
ASX:NXS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Next Science Ltd
ASX:NXS
|
AU |
|
Greenwing Resources Ltd
ASX:GW1
|
AU |
|
Takase Corp
TSE:9087
|
JP |
Next Science Ltd
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2019-04-18. The firm's principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The firm's product includes XPERIENCE, SURGX, BACTISURE and BLASTX. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SURGX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel. The BLASTX is an antimicrobial wound gel.
Product Sales: Next Science reported product sales of $5.3 million for Q1 FY25, a 3% decrease from the same period last year.
Direct Sales Performance: Direct product sales were $3.7 million, down 14% year-on-year due to weaker DME sales, though XPERIENCE and BLASTX saw strong growth.
Gross Margin: Gross margin improved to 84% in Q1 FY25, up from 79% a year ago and 83% in the previous quarter, benefiting from a shift in product mix.
Cash Position: Cash receipts for the quarter were $4.7 million, down 13% year-on-year, with closing cash of $1.3 million and debt at $3.0 million.
FDA Warning Letter: Management addressed the FDA warning letter received in February 2025, stating that product manufacturing and sales have continued uninterrupted.
